Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Treasury Shares (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Treasury Shares over the past 7 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Treasury Shares at $1.1 million for Q4 2025, up 238.89% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (up 238.89% YoY), and the annual figure for FY2025 was $1.1 million, up 238.89%.
  • Treasury Shares for Q4 2025 was $1.1 million at Viridian Therapeutics, Inc.\DE, down from $1.1 million in the prior quarter.
  • Over the last five years, Treasury Shares for VRDN hit a ceiling of $1.1 million in Q2 2025 and a floor of $88875.0 in Q3 2023.
  • Median Treasury Shares over the past 3 years was $669096.0 (2024), compared with a mean of $656071.0.
  • Peak annual rise in Treasury Shares hit 478.95% in 2024, while the deepest fall reached 60.98% in 2024.
  • Viridian Therapeutics, Inc.\DE's Treasury Shares stood at $804947.0 in 2023, then tumbled by 60.98% to $314075.0 in 2024, then surged by 238.89% to $1.1 million in 2025.
  • The last three reported values for Treasury Shares were $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.